Dyadic International Inc

Dyadic International Inc. a biotechnology platform company develops produces and sells enzymes and other proteins in the United States. It utilizes its patented and proprietary C1 platform and other technologies to conduct research development and commercial activities for the development and manufacturing of human and animal vaccines and drugs such as virus-like particles protein antigens ferritin nanoparticles monoclonal antibodies bi/tri-specific antibodies fab antibody fragments Fc-fusion proteins biosimilars and/or biobetters and other therapeutic enzymes and proteins. The company offers DYAI-100 SARS-CoV-2-RBD antigen vaccine candidate towards a first-in-human Phase 1 clinical trial is to demonstrate the safety in humans of a protein produced from C1-cell protein production platform. It has a research and development agreement with VTT Technical Research Centre of Finland Ltd.; and strategic research services agreement with Biotechnology Developments for Industry in Pharmaceuticals S.L.U. as well as co-development and marketing agreement with Fermbox Bio Inc to design Develop and commercialize animal free alternative proteins and biomaterials The company was founded in 1979 and is headquartered in Jupiter Florida.